Document is current
Any future updates will be listed below
-
Authors
Hong, Lingzhi https://orcid.org/0000-0001-6553-3279
Patel, Sonia
Drusbosky, Leylah M.
Xiong, Yuanyuan
Chen, Rongrong
Geng, Ruixuan
Heeke, Simon https://orcid.org/0000-0002-5916-534X
Nilsson, Monique
Wu, Jia https://orcid.org/0000-0001-8392-8338
Heymach, John V. https://orcid.org/0000-0001-9068-8942
Wang, Yingyi
Zhang, Jianjun https://orcid.org/0000-0001-7872-3477
Le, Xiuning https://orcid.org/0000-0002-8554-1185
- License Information
-
More Information
Article History
Received: 6 September 2023
Accepted: 22 September 2024
First Online: 1 October 2024
Competing interests
: L.M.D. is employee and stockholder of Guardant Health. Y.X. and R.C. are employee of Geneplus-Beijing. S.H. received consulting fees from Guardant health and AstraZeneca. M.N. receives royalties and licensing fees from Spectrum Pharmaceuticals. J.V.H. reports receiving advisory/consulting fees from AstraZeneca, Boehringer-Ingeheim, Catalyst, Genentech, GlaxoSmithKline, Guardant Health, Foundation Medicine, Hengrui Therapeutics, Eli Lilly, Novartis, Spectrum, Sanofi, Takeda Pharmaceuticals, Mirati Therapeutics, Bristiol-Myers Squibb, BrightPath Biotherapeutics, Janssen Global Services, Nexus Health Systems, EMD Serono, Pneuma Respiratory, Kairos Venture Investments, Leads Biolabs, RefleXion, and research funding from GlaxoSmithKline, AstraZeneca, Spectrum, all outside of the submitted work. J.Z. reports grants from Merck, grants and personal fees from Johnson and Johnson and Novartis, and personal fees from Bristol Myers Squibb, AstraZeneca, GenePlus, Innovent, and Hengrui outside the submitted work. X.L. receives consulting/advisory fees from EMD Serono (Merck KGaA), AstraZeneca, Spectrum Pharmaceutics, Novartis, Eli Lilly, Boehringer Ingelheim, Hengrui Therapeutics, Janssen, Blueprint Medicines, Regeneron, Sensei Biotherapeutics, Abion, Pinetree Therapeutics and Abbvie, and Research Funding from Eli Lilly, EMD Serono, ArriVent, Teligene, Regeneron, Blackdiamond, and Boehringer Ingelheim. The other authors declare no competing interests in the submitted work.
